Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in Active Ankylosing Spondylitis
NCT03117270Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Mar 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Filgotinib with Placebo (2 arms). Primary endpoint: Ankylosing Spondylitis Disease Activity Score at 12 weeks. Started Mar 2017; status: completed.
02
Drugs
filgotinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT03117270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03117270.